NCT07028008View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

NANot yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

May 28, 2027

Study Completion Date

May 28, 2029

Conditions
Melanoma
Interventions
BIOLOGICAL

tumor-infiltrating lymphocyte (TIL)

tumor-infiltrating lymphocyte (TIL): CT-SP 1\~100 x10 9 cells

All Listed Sponsors
lead

Samsung Medical Center

OTHER